Highlight

Programmed Death-1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy^†

Corresponding Author

Prof. Alexander Dömling

[email protected]

Department for Drug Design, University of Groningen, A. Deusinglaan 1, 9700 AD Groningen (The Netherlands) http://www.drugdesign.nl/

Alexander Dömling, Department for Drug Design, University of Groningen, A. Deusinglaan 1, 9700 AD Groningen (The Netherlands) http://www.drugdesign.nl/

Tad A. Holak, Department of Organic Chemistry, Jagiellonian University, Ingardena 3, 30-060 Cracow (Poland)

Search for more papers by this author

Prof. Tad A. Holak,

Corresponding Author

Prof. Tad A. Holak

[email protected]

Department of Organic Chemistry, Jagiellonian University, Ingardena 3, 30-060 Cracow (Poland)

Alexander Dömling, Department for Drug Design, University of Groningen, A. Deusinglaan 1, 9700 AD Groningen (The Netherlands) http://www.drugdesign.nl/

Tad A. Holak, Department of Organic Chemistry, Jagiellonian University, Ingardena 3, 30-060 Cracow (Poland)

Search for more papers by this author

Prof. Alexander Dömling,

Corresponding Author

Prof. Alexander Dömling

[email protected]

Department for Drug Design, University of Groningen, A. Deusinglaan 1, 9700 AD Groningen (The Netherlands) http://www.drugdesign.nl/

Alexander Dömling, Department for Drug Design, University of Groningen, A. Deusinglaan 1, 9700 AD Groningen (The Netherlands) http://www.drugdesign.nl/

Tad A. Holak, Department of Organic Chemistry, Jagiellonian University, Ingardena 3, 30-060 Cracow (Poland)

Search for more papers by this author

Prof. Tad A. Holak,

Corresponding Author

Prof. Tad A. Holak

[email protected]

Department of Organic Chemistry, Jagiellonian University, Ingardena 3, 30-060 Cracow (Poland)

Alexander Dömling, Department for Drug Design, University of Groningen, A. Deusinglaan 1, 9700 AD Groningen (The Netherlands) http://www.drugdesign.nl/

Tad A. Holak, Department of Organic Chemistry, Jagiellonian University, Ingardena 3, 30-060 Cracow (Poland)

Search for more papers by this author

First published: 28 January 2014

https://doi.org/10.1002/anie.201307906

Citations: 63

^†

A.D. thanks the National Institute of Health (1R01GM09708201), Innovative Medicines Initiative (IMI) and the Qatar National Research Foundation (NPRP6-065-3-012) for funding. T.A.H. is funded by a Marie Curie FP7-Reintegration-Grant within the 7th EC Framework Programme and by a Project operated within the Foundation for Polish Science TEAM Programme, cofinanced by the EU European Regional Development Fund.

Share a link

Email
Wechat
Bluesky

Graphical Abstract

No other cancer therapy target class caused more excitement than the programmed death-1 (PD-1) pathway related. Antibodies against PD-1 and PD-1 ligands represent a therapeutic breakthrough and are the first examples of broadly efficacious and durable cancer immunotherapies. Cancer for the first time seems to have transformed from an often incurable to a “clinically manageable” disease.

References

1W. B. Coley, Am. J. Med. Sci. 1893, 105, 487–511.
10.1097/00000441-189305000-00001
Google Scholar
2P. Ehrlich, Ned. Tijdschr. Geneeskd. 1909, 53, 273–290.
Google Scholar
3C. Milstein, Bioessays 1999, 21, 966–973.
10.1002/(SICI)1521-1878(199911)21:11<966::AID-BIES9>3.0.CO;2-Z
CAS PubMed Web of Science® Google Scholar
4S. A. Sherwin, J. A. Knost, S. Fein, P. G. Abrams, K. A. Foon, J. J. Ochs, C. Schoenberger, A. E. Maluish, R. K. Oldham, J. Am. Med. Assoc. 1982, 248, 2461–2466.
CAS PubMed Web of Science® Google Scholar
5S. A. Rosenberg, M. T. Lotze, J. C. Yang, S. L. Topalian, A. E. Chang, D. J. Schwartzentruber, P. Aebersold, S. Leitman, W. M. Linehan, C. A. Seipp, D. E. White, S. M. Steinberg, J. Natl. Cancer Inst. 1993, 21, 622–632.
10.1093/jnci/85.8.622
Web of Science® Google Scholar
6C. Robert, J.-C. Soria, A. M. M. Eggermont, Eur. J. Cancer 2013, 49, 2968–2971.
10.1016/j.ejca.2013.07.001
CAS PubMed Web of Science® Google Scholar
7A. M. M. Eggermont, C. Robert, Eur. J. Cancer 2011, 47, 2150–2157.
10.1016/j.ejca.2011.06.052
PubMed Web of Science® Google Scholar
8O. Hamid, R. D. Carjaval, Expert Opin. Biol. Ther. 2013, 13, 847–861.
10.1517/14712598.2013.770836
CAS PubMed Web of Science® Google Scholar
9M. Sznol, H. M. Kluger, F. S. Hodi, et al., J. Clin. Oncol. 2013, 31 (Suppl.) [abstr. CRA9006].
Google Scholar
10O. Hamid, C. Robert, A. Daud, F. S. Hodi, W. J. Hwu, R. Kefford, J. D. Wolchok, P. Hersey, R. W. Joseph, J. S. Weber, R. Dronca, T. C. Gangadhar, A. Patnaik, H. Zarour, A. M. Joshua, K. Gergich, J. Elassaiss-Schaap, A. Algazi, C. Mateus, P. Boasberg, P. C. Tumeh, B. Chmielowski, S. W. Ebbinghaus, X. N. Li, S. P. Kang, A. Ribas, N. Engl. J. Med. 2013, 369, 134–144.
10.1056/NEJMoa1305133
CAS PubMed Web of Science® Google Scholar
11G. Bollag, P. Hirth, J. Tsai, J. Zhang, P. N. Ibrahim, H. Cho, W. Spevak, C. Zhang, Y. Zhang, G. Habets, E. Burton, B. Wong, G. Tsang, B. L. West, B. Powell, R. Shellooe, A. Marimuthu, H. Nguyen, K. Y. J. Zhang, D. R. Artis, J. Schlessinger, F. Su, B. Higgins, R. Iyer, K. D′Andrea, A. Koehler, M. Stumm, P. S. Lin, R. J. Lee, J. Grippo, I. Puzanov, K. B. Kim, A. Ribas, G. A. McArthur, J. A. Sosman, P. B. Chapman, K. T. Flaherty, X. W. Xu, K. L. Nathanson, K. Nolop, Nature 2010, 467, 596–599.
10.1038/nature09454
CAS PubMed Web of Science® Google Scholar
12G. Suntharalingam, M. R. Perry, S. Ward, S. J. Brett, A. Castello-Cortes, M. D. Brunner, N. Panoskaltsis, N. Engl. J. Med. 2006, 355, 1018–1028.
10.1056/NEJMoa063842
CAS PubMed Web of Science® Google Scholar
13S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. P. Chen, W. H. Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Y. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton, M. Sznol, N. Engl. J. Med. 2012, 366, 2443–2454.
10.1056/NEJMoa1200690
CAS PubMed Web of Science® Google Scholar
14A. Mullard, Nat. Rev. Drug Discovery 2013, 12, 489–492.
10.1038/nrd4066
CAS PubMed Web of Science® Google Scholar
15J. D. Wolchok, H. M. Kluger, M. K. Callahan, et al., 2013 ASCO Annual Meeting 2013, Abstract 9012;
Google Scholar
J. D. Wolchok, H. M. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, N. H. Segal, C. E. Ariyan, R. A. Gordon, K. Reed, M. M. Burke, A. Caldwell, S. A. Kronenberg, B. U. Agunwamba, X. L. Zhang, I. Lowy, H. D. Inzunza, W. Feely, C. E. Horak, Q. Hong, A. J. Korman, J. M. Wigginton, A. Gupta, M. Sznol, N. Engl. J. Med. 2013, 369, 122–133.
10.1056/NEJMoa1302369
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume53, Issue9

February 24, 2014

Pages 2286-2288

Programmed Death-1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy^†

Graphical Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Programmed Death-1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy†

Graphical Abstract

References

Citing Literature

References

Related

Information

Programmed Death-1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy^†